CLOs on the Move


 
As a nonprofit engineering innovation company, Draper serves our nation`s interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers` needs and to deliver new capabilities to them.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.draper.com
  • 555 Technology Square
    Cambridge, MA USA 02139
  • Phone: 617.258.1000

Executives

Name Title Contact Details
Mary Kim
Vice President, General Counsel and Secretary Profile

Similar Companies

Gradientech

Gradientech is developing the microfluidic platform of tomorrow, today. Our revolutionising in vitro diagnostic system, QuickMIC®, is designed to strengthen labs by providing reliable results, at outstanding speed. Visit to experience how.

Anixa Biosciences

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.

Ohana Biosciences

Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.

Millennium Pharmaceuticals Inc

Millennium, a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering

Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.